• 

  Inactivated vaccines safest with lesser adverse reactions: Bharat Biotech

  India | December 21, 2020 8:11 IST

  About 755 participants have been vaccinated in phase 1 & 2 clinical trials. No serious adverse events have been reported to be related to the vaccine in phase 1 and 2 clinical trials, Bharat Biotech said.

• 

  Shortfall in Phase-III Covaxin trial target, can delay rollout: AIIMS doctor

  India | December 18, 2020 13:49 IST

  The rollout of Covid-19 vaccine by Bharat Biotech for the general public may get delayed as the All India Institute of Medical Sciences (AIIMS), where its Phase-III human clinical trial is underway, is struggling to find takers of the trial shots, the official heading the project told IANS.

• 

  Covaxin 'well tolerated' in all dose groups, no serious adverse events in phase 1 trials

  India | December 16, 2020 20:24 IST

  Bharat Biotech's Covaxin was "well-tolerated" in all dose groups, the company said Wednesday as it released interim findings of phase 1 trials.

• 

  'DCGI seeking more data for emergency use authorisation won't impact timeline for vaccine roll-out'

  India | December 15, 2020 22:21 IST

  The applications of Bharat Biotech, Serum Institute and Pfizer seeking emergency use authorisation for their COVID-19 vaccines are being examined, the Centre said on Tuesday asserting that drug regulator DCGI seeking more data from these companies will not impact the vaccine-roll out timeline.  

• 

  FACT CHECK: Serum Institute, Bharat Biotech's proposals for emergency use of COVID vaccine rejected?

  India | December 09, 2020 18:34 IST

  Amid a race to get the best COVID-19 vaccine, rumour mills are also abuzz with one speculation or the other. The Ministry of Health and Family Welfare today denied a report about the rejection of Serum Institute of India and Bharat Biotech's emergency-use authorisation of their respective vaccines. It said that the report was "fake".

• 

  Over 60 envoys visit Bharat Biotech facility in Hyderabad

  India | December 09, 2020 14:54 IST

  The visit by the heads of foreign missions arranged by the Ministry of External Affairs (MEA) is part of India's efforts to develop partnerships for the manufacture and delivery of vaccines.

• 

  Hyderabad: 64 envoys visit two biotech companies developing Covid vaccines

  News | December 09, 2020 14:00 IST

  India COVID Vaccine: Last month, the Foreign Ministry had briefed over 190 heads of diplomatic missions and representatives of leading international organisations on Covid-related issues.

• 

  Covaxin likely to be available for public use by February end

  Good News | December 08, 2020 21:55 IST

  Covaxin, the COVID vaccine candidate by Hyderabad-based vaccine manufacturer Bharat Biotech Limited, being developed in collaboration with the Indian Council of Medical Research (ICMR), is likely to be available for use of the general public by the end of February 2021, Dr Sanjay Roy, principal investigator (PI) heading its clinical trial at AIIMS, told IANS on Tuesday.

• 

  Bharat Biotech applies for emergency use authorisation for Covaxin

  India | December 07, 2020 21:55 IST

  After vaccine major Serum Institute of India (SII), Bharat Biotech on Monday applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed coronavirus vaccine called Covaxin.

• 

  Super 100 | Covaxin's efficacy determined 14 days post 2nd dose: Bharat Biotech

  News | December 05, 2020 17:12 IST

  Just hours after Haryana Health minister Anil Vij, who took a trial dose of Covaxin a fortnight ago, tested positive for coronavirus on Saturday, the vaccine developer Bharat Biotech issued a statement saying, ''Covaxin is designed to be efficacious''.
  
  The vaccine developer said that the clinical trials are based on a 2-dose schedule, given 28 days apart, and vaccine efficacy will be determined 14 days after the second dose.